NCT01984398View on ClinicalTrials.gov

Comparison of Two Formulations of Androxal

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Bioequivalence
Interventions
DRUG

12.5 mg Androxal Formulation A

Single dose of 12.5 mg Androxal formulation A

DRUG

12.5 mg Androxal Formulation B

Single dose of 12.5 mg Androxal Formulation B

DRUG

25 mg Androxal Formulation A

Single dose of 25 mg Androxal formulation A

DRUG

25 mg Androxal Formulation B

Single dose of 25 mg Androxal formulation B

Trial Locations (1)

30014-3616

Clinical Pharmacology of miami, Miami

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT01984398 - Comparison of Two Formulations of Androxal | Biotech Hunter | Biotech Hunter